Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
Markowitz M, Slater LN, Schwartz R, Kazanjian PH, Hathaway B, Wheeler D, Goldman M, Neubacher D, Mayers D, Valdez H, McCallister S. Markowitz M, et al. Among authors: valdez h. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):401-10. doi: 10.1097/QAI.0b013e318074eff5. J Acquir Immune Defic Syndr. 2007. PMID: 17554217 Clinical Trial.
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.
McCallister S, Valdez H, Curry K, MacGregor T, Borin M, Freimuth W, Wang Y, Mayers DL. McCallister S, et al. Among authors: valdez h. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):376-82. doi: 10.1097/00126334-200404010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15097154 Clinical Trial.
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. Hicks CB, et al. Among authors: valdez h. Lancet. 2006 Aug 5;368(9534):466-75. doi: 10.1016/S0140-6736(06)69154-X. Lancet. 2006. PMID: 16890833
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C, Tawadrous M. Vernazza P, et al. Among authors: valdez h. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):171-9. doi: 10.1097/QAI.0b013e31827a2ba2.. J Acquir Immune Defic Syndr. 2013. PMID: 23328090 Clinical Trial.
Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
Ghosn J, Quinson AM, Sabo N, Cotte L, Piketty C, Dorléacq N, Bravo ML, Mayers D, Harmenberg J, Mårdh G, Valdez H, Katlama C. Ghosn J, et al. Among authors: valdez h. HIV Med. 2007 Apr;8(3):142-7. doi: 10.1111/j.1468-1293.2007.00444.x. HIV Med. 2007. PMID: 17461857 Free article. Clinical Trial.
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. McGovern RA, et al. Among authors: valdez h. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf. J Acquir Immune Defic Syndr. 2012. PMID: 23095934 Clinical Trial.
219 results